Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 5 Other hematologic neoplasm 3 Breast 3 Lymphoid 2 Genitourinary 2 Thoracic 1 Sarcoma 1 Plasma cell 1 Myeloid 1 Gastrointestinal 1

Conditions

Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1174 Cisplatin 891 Pemetrexed 847 pembrolizumab 626 Paclitaxel 609 Docetaxel 539 Gemcitabine 428 Radiotherapy 393 Erlotinib Hydrochloride 381 Nivolumab 344 Bevacizumab 337 Etoposide 297 durvalumab 264 Drug Therapy 260 osimertinib 237 atezolizumab 225 Radiosurgery 196 Gefitinib 186 Vinorelbine 149 Magnetic Resonance Spectroscopy 132 Ipilimumab 129 130-nm albumin-bound paclitaxel 125 Cetuximab 113 Blood Specimen Collection 106 anlotinib 105 tislelizumab 103 Topotecan 103 Specimen Handling 102 Surgical Procedures, Operative 101 Cyclophosphamide 101

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

flt3 ligand protein × Thoracic × Clear all

NCT04491084 2024-02-28

FLT3

Albert Einstein College of Medicine

Phase 1/2 Terminated

5 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡